High incidence of HER-2 positivity in inflammatory breast cancer
High incidence of HER-2 positivity in inflammatory breast cancer
复制标题
DOI：
10.1016/j.breast.2003.08.004
复制
发表时间：
2004-04-01
期刊：
影响因子：
3.9
通讯作者：
Smith, IE
中科院分区：
文献类型：
--
作者：
Parton, M;Dowsett, M;Smith, IE
HER-2在约25%的人类乳腺癌中过度表达，并且与不良结局相关。我们研究了HER-2状态在炎性乳腺癌（IBC）中的发生率。研究了49例新诊断的IBC。使用HercepTest（TM）和FISH测定法对福尔马林固定的石蜡包埋的治疗前组织活组织检查HER-2蛋白和基因的过度表达。比较HER-2阳性（HercepTest（TM）评分3+和FISH阳性）和阴性组之间的临床结果。52%的IBC检测为HER-2阳性。HER-2阳性组与HER-2阴性组在人口统计学上相当。96%的HER-2阳性患者对原发性化疗有反应，而HER-2阴性患者为76%（P = 0.09）。两组之间的结果无显著差异。结论：HER-2蛋白在IBC中的过度表达率高于非IBC。早期HER-2导向治疗（如单克隆抗体曲妥珠单抗）作为多模式治疗的一部分，可能会改善这种预后不良癌症的结局。(C)2003爱思唯尔有限公司。保留所有权利。
HER-2 is over-expressed in around 25% of human breast cancers, and is associated with poor outcome. We examined the incidence of HER-2 status in inflammatory breast cancer (IBC). Forty-nine newly diagnosed IBCs were studied. Formalin-fixed paraffin-embedded pre-treatment tissue biopsies were examined immunohistochemically for the over-expression of the HER-2 protein and gene using the HercepTest(TM) and FISH assay. Clinical outcome was compared between the HER-2 positive (HercepTest(TM) score 3+ and FISH positive) and negative groups. Fifty-two per cent of the IBCs examined were HER-2 positive. The HER-2 positive group were demographically comparable to the HER-2 negative group. Ninety-six per cent of the HER-2 positive patients responded to primary chemotherapy compared to 76% of the HER-2 negative (P = 0.09). No significant differences in outcome emerged between the two groups. In conclusion, this study found the incidence of HER-2 protein over-expression in IBC is higher than previously reported in non-IBC. Early HER-2 directed therapy (such as the monoclonal antibody trastuzumab) as a part of multimodal treatment may improve outcome in this poor prognosis cancer. (C) 2003 Elsevier Ltd. All rights reserved.